NL-OMON48409已完成不适用
A randomized, placebo-controlled, double-blind phase I study to explore safety, tolerability and pharmacodynamics of Cypep-1 in subjects with cutaneous warts - A Phase 1 Safety and PD Study of CyPep-1 in Subjects with Cutaneous Warts
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy subjects (male, non-pregnant female), 18 to 65 years of age, inclusive. (Healthy status is defined by absence of evidence of any clinical significant/uncontrolled active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs,12-lead ECG, haematology, blood chemistry, and urinalysis);
- •2. Body mass index (BMI) between 18 and 35 kg/m2, inclusive;
- •3. Free of clinically significant systemic or dermatologic disorders, which, in the opinion of the investigator, will interfere with the study results or increase the risk of Adverse Events;
- •4. Have at least 1 (non- peri / subungual) common wart on the, preferably, dorsal side of the hand /fingers which is 3-10 mm (inclusive) in diameter in its longest dimension on the plane of the skin;
- •5. If female of childbearing potential, have a negative urine pregnancy test at Screening/Day 0, and is willing to use effective contraception during the study (i.e. oral, implanted, injectable, IUD, diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy);
- •6. Able to participate and willing to give written informed consent and to comply with the study restrictions;
- •7. Ability to communicate well with the investigator in the Dutch language;
- •8. Willing to refrain from using cosmetics or other topical products in the treatment area for the duration of the study;
- •9. Agree not to use wart-removing products (prescription or over-the-counter) in the target area or prohibited medications other than the study medication during the course of the study.
排除标准
- •Eligible subjects must meet none of the following exclusion criteria:
- •1. Any clinically significant abnormality as determined by medical history taking and physical examinations obtained during the screening visit that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
- •2. Not willing to use effective (double barrier) contraception until at least 3 months after last study drug application;
- •3. For women: a positive pregnancy test and/or breastfeeding at screening or women who plan to become pregnant;
- •4. A positive test for drugs of abuse at screening;
- •5. History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption > 21 units/week);
- •6. Positive test results for Hepatitis B, Hepatitis C or HIV;
- •7. Have used salicylic acid or any other over-the-counter wart-removing product including cryo-therapy in the treatment area within 28 days prior to first study drug application;
- •8. Have required systemic intake of immunosuppressive or immunomodulatory medication (including oral or parenteral corticosteroids) within 60 days prior to first study drug application or during the course of the study. Routine use of inhaled or intranasal corticosteroids during the study is allowed;
- •9. Have any current and / or recurrent clinical significant skin infection in the treatment area other than common warts;
- •10. Have a known sensitivity to any of the investigational product ingredients;
- •11. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year;
- •12. Donation of blood or blood loss of >500 mL within 3 months prior to screening or donation of plasma within 14 days
- •13. Not having a general practitioner;
- •14. Not willing to give permission to have the general practitioner to be notified upon participation in this study;
- •15. Any condition that in the opinion of the investigator would complicate or compromise the study or the well-being of the subject.;Part 2 only:
- •16. Have treatment resistant / persistent warts as defined as one of the following:
- •a. More than 5 different failed treatments including topical formulations and cryotherapy
- •b. Longer than 6 years presence of the target wart
- •c. Having received active treatment in a clinical trial with an experimental drug for cutaneous warts.
研究者
相似试验
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. - Phase III study of recombinant human C1 inhibitorPatients with acute attacks of hereditary angioedemaMedDRA version: 8Level: LLTClassification code 10019860EUCTR2005-000206-31-ESaboratorios Dr. Esteve, S.A.32
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. - Phase III study of recombinant human C1 inhibitorPatients with acute attacks of hereditary angioedema.MedDRA version: 9.1 Level: LLT Classification code 10019860 Term: Hereditary angioedemaEUCTR2005-000206-31-GBPharming Technologies B.V.32
进行中（未招募）
不适用
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedemaEUCTR2004-004282-15-ITPHARMING TECHNOLOGIES B.V.
进行中（未招募）
不适用
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedemaEUCTR2005-000206-31-ITPHARMING TECHNOLOGIES B.V.
已完成
不适用
Evaluation of the safety, tolerability and pharmacokinetics of repeated oral doses of Priaculin in healthy male volunteersHealthy male volunteersISRCTN32485300Dr. Willmar Schwabe GmbH & Co. KG (Germany)32